Loading...
Docoh

Dexcom (DXCM)

News

From Benzinga Pro
Citigroup Maintains Buy on DexCom, Lowers Price Target to $525
17 May 22
News, Price Target, Analyst Ratings
Citigroup analyst Joanne Wuensch maintains DexCom (NASDAQ:DXCM) with a Buy and lowers the price target from $630 to $525.
DexCom Earnings Perspective: Return On Invested Capital
5 May 22
Earnings
Pulled from Benzinga Pro data, DexCom (NASDAQ:DXCM) posted Q1 earnings of $97.30 million, an increase from Q4 of 601.55%. Sales dropped to $628.80 million, a 9.94% decrease between quarters.
If You Invested $1000 In DexCom 10 Years Ago, Here's How Much You Would Have Today
2 May 22
Earnings, News, Dividends
DexCom (NASDAQ:DXCM) has outperformed the market over the past 10 years by 32.66% on an annualized basis producing an average annual return of 44.4%. Currently, DexCom has a market capitalization of $39.95 billion.
Read Here Why Did This Analyst Cut DexCom's Price Target
29 Apr 22
Analyst Color, Earnings, News, Health Care, Price Target, Analyst Ratings, General
Raymond James Maintains Outperform on DexCom, Lowers Price Target to $486
29 Apr 22
News, Price Target, Analyst Ratings
Raymond James analyst Jayson Bedford maintains DexCom (NASDAQ:DXCM) with a Outperform and lowers the price target from $538 to $486.
Morgan Stanley Maintains Equal-Weight on DexCom, Lowers Price Target to $492
29 Apr 22
News, Price Target, Analyst Ratings
Morgan Stanley analyst David Lewis maintains DexCom (NASDAQ:DXCM) with a Equal-Weight and lowers the price target from $514 to $492.
Piper Sandler Maintains Overweight on DexCom, Lowers Price Target to $480
29 Apr 22
News, Price Target, Analyst Ratings
Piper Sandler analyst Matt O'Brien maintains DexCom (NASDAQ:DXCM) with a Overweight and lowers the price target from $725 to $480.
SVB Leerink Maintains Outperform on DexCom, Lowers Price Target to $500
29 Apr 22
News, Price Target, Analyst Ratings
SVB Leerink analyst Danielle Antalffy maintains DexCom (NASDAQ:DXCM) with a Outperform and lowers the price target from $565 to $500.
Recap: DexCom Q1 Earnings
28 Apr 22
Earnings
DexCom (NASDAQ:DXCM) reported its Q1 earnings results on Thursday, April 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings DexCom missed estimated earnings by 38.46%, reporting an EPS of $0.32 versus an estimate of $0.52.
DexCom Q1 EPS $0.32 Misses $0.52 Estimate, Sales $628.80M Beat $623.36M Estimate
28 Apr 22
Earnings, News
DexCom (NASDAQ:DXCM) reported quarterly earnings of $0.32 per share which missed the analyst consensus estimate of $0.52 by 38.46 percent. This is a 3.03 percent decrease over earnings of $0.33 per share from the same
Earnings Scheduled For April 28, 2022
28 Apr 22
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • PBF Energy (NYSE:PBF) is projected to report quarterly earnings at $0.26 per share on revenue of $8.24 billion.
DexCom's Earnings: A Preview
27 Apr 22
Earnings
DexCom (NASDAQ:DXCM) is set to give its latest quarterly earnings report on Thursday, 2022-04-28. Here's what investors need to know before the announcement. Analysts estimate that DexCom will report an earnings per share (EPS) of $0.52.
Insulet Highlights New Data For Omnipod 5 System For Type 1, Type 2 Diabetes
27 Apr 22
Large Cap, News, Health Care, General
Markets Fall Sharply Amid Ongoing Rate Hike Concerns
22 Apr 22
News, After-Hours Center, Markets, Movers, Trading Ideas
The S&P 500 traded lower for the third week in a row as investors brace for a potential 0.5% interest rate hike by the Federal Reserve.
12 Health Care Stocks Moving In Tuesday's After-Market Session
19 Apr 22
Movers
Gainers
Here's How Much $100 Invested In DexCom 5 Years Ago Would Be Worth Today
6 Apr 22
Earnings, News, Dividends
DexCom (NASDAQ:DXCM) has outperformed the market over the past 5 years by 32.15% on an annualized basis producing an average annual return of 45.92%. Currently, DexCom has a market capitalization of $49.71 billion.
Markets Have Another Strong Week As S&P 500 Erases Initial Losses From Russia-Ukraine War
25 Mar 22
News, After-Hours Center, Markets, Movers, Trading Ideas
U.S. indices finished mixed Friday to conclude the trading week. Oil prices gained during Friday's session, which has continued to pressure economic sentiment. The S&P 500 traded higher for the second week in a row and has now more than erased its initial losses following the Russian invasion of Ukraine.
Markets Fall In Anticipation Of This Week's Fed Decision
14 Mar 22
News, After-Hours Center, Markets, Movers, Trading Ideas
U.S. indices finished lower Monday amid continued Russia-Ukraine uncertainty, as well as in anticipation of this week’s Fed decision.
Dexcom G7 Continuous Glucose Monitoring System Receives European CE Mark
14 Mar 22
News, Health Care, General
DexCom Inc's (NASDAQ: DXCM) Dexcom G7 Continuous Glucose Monitoring (CGM) System has
Dexcom G7 Continuous Glucose Monitoring System Received CE Mark
14 Mar 22
News, Eurozone, Markets
DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today it has secured CE Mark (Conformité Européenne) for the Dexcom G7 Continuous Glucose Monitoring (CGM) System for people with diabetes in Europe age two years and older, including pregnant women.

Press releases

From Benzinga Pro
Dexcom Updates First Quarter 2022 Conference Call for April 28, 2022 at 5:30 p.m. Eastern Time
28 Apr 22
Press Releases
DexCom, Inc. has updated its first quarter 2022 earnings call due to technical difficulties with the conference call provider. The conference call will now start at 5:30 p.m. (Eastern Time). The link to the webcast will
Dexcom Reports First Quarter 2022 Financial Results
28 Apr 22
Press Releases
DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter ended March 31, 2022. First Quarter 2022 Financial Highlights: Revenue grew 25% versus the same quarter of the prior year to
DexCom Showcases Expanded CGM Portfolio at International ATTD Conference, Offering More Choice to People With Diabetes
26 Apr 22
Press Releases
New portfolio of continuous glucose monitoring systems includes Dexcom ONE, Dexcom G6 and the upcoming Dexcom G7, which recently received CE Mark and is currently under FDA review1 The expanded range of products
Dexcom Publishes Annual Sustainability Report
7 Apr 22
Press Releases
Report advances Dexcom's environmental, social, and governance (ESG) transparency by providing new disclosures including company's first Sustainability Accounting Standards Board (SASB) index DexCom, Inc.
Dexcom Schedules First Quarter 2022 Earnings Release and Conference Call for April 28, 2022 at 4:30 p.m. Eastern Time
31 Mar 22
Press Releases
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2022 financial results after market close on Thursday, April 28, 2022. Management will hold a conference call to review the
Dexcom G7 Receives CE Mark – Next-Generation Continuous Glucose Monitoring System to Revolutionize Diabetes Management
14 Mar 22
Press Releases
The best-selling real-time CGM in the world1 is now more powerful and easier to use with a small, all-in-one wearable and completely redesigned mobile app New system has the fastest sensor warmup on the market,*
Ontario Announces Public Coverage for the Dexcom G6 Continuous Glucose Monitoring System under the Assistive Devices Program
7 Mar 22
Press Releases
Dexcom CGM use is proven to improve glycemic control1,2 and can reduce the risk of costly long-term diabetes-related complications compared to fingerstick monitoring.3 Dexcom, Inc. (NASDAQ:DXCM), the global leader in
FDA Grants Breakthrough Device Designation for Dexcom Hospital CGM System
1 Mar 22
Press Releases
Dexcom CGM to be evaluated for performance in the hospital and for the potential of more effective glycemic management and improved patient outcomes in the hospital setting Breakthrough Device Designation from the
GraphWear Brings On Former Dexcom and Fitbit Veterans To Scale First-of-its-Kind Health Monitoring Platform
17 Feb 22
News, Press Releases
GraphWear, the company pioneering needle-free disease monitoring, today announced an executive hire and a new board member. Dana Cambra and Woody Scal will serve as key players in driving the company's mission